Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Changes in body composition during and after adjuvant or neo-adjuvant chemotherapy in women with breast cancer stage I-IIIB compared with changes over a similar timeframe in women without cancer.

van den Berg MMGA, Kok DE, Visser M, de Vries JHM, de Kruif JTCM, de Vries Y, Posthuma L, Sommeijer DW, Timmer-Bonte A, Los M, van Laarhoven HWM, Kampman E, Winkels RM.

Support Care Cancer. 2019 Jul 9. doi: 10.1007/s00520-019-04951-6. [Epub ahead of print]

PMID:
31290019
2.

MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis.

van Loo PF, Hangalapura BN, Thordardottir S, Gibbins JD, Veninga H, Hendriks LJA, Kramer A, Roovers RC, Leenders M, de Kruif J, Doornbos RP, Sirulnik A, Throsby M, Logtenberg T, Dolstra H, Bakker ABH.

Expert Opin Biol Ther. 2019 Jul;19(7):721-733. doi: 10.1080/14712598.2019.1623200.

PMID:
31286786
3.

A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol.

de Kruif JTCM, Visser M, van den Berg MMGA, Derks MJM, de Boer MR, van Laarhoven HWM, de Vries JHM, de Vries YC, Kampman E, Winkels RW, Westerman MJ.

BMC Cancer. 2019 Jan 5;19(1):7. doi: 10.1186/s12885-018-5207-7.

4.

The randomised uterine septum transsection trial (TRUST): design and protocol.

Rikken JFW, Kowalik CR, Emanuel MH, Bongers MY, Spinder T, de Kruif JH, Bloemenkamp KWM, Jansen FW, Veersema S, Mulders AGMGJ, Thurkow AL, Hald K, Mohazzab A, Khalaf Y, Clark TJ, Farrugia M, van Vliet HA, Stephenson MS, van der Veen F, van Wely M, Mol BWJ, Goddijn M.

BMC Womens Health. 2018 Oct 5;18(1):163. doi: 10.1186/s12905-018-0637-6.

5.

Perceptions of Dutch health care professionals on weight gain during chemotherapy in women with breast cancer.

de Kruif JTCM, Scholtens MB, van der Rijt J, de Boer MR, van den Berg MMGA, de Vries YC, Winkels RM, Visser M, Kampman E, Westerman MJ.

Support Care Cancer. 2019 Feb;27(2):601-607. doi: 10.1007/s00520-018-4347-2. Epub 2018 Jul 19.

6.

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.

Geuijen CAW, De Nardis C, Maussang D, Rovers E, Gallenne T, Hendriks LJA, Visser T, Nijhuis R, Logtenberg T, de Kruif J, Gros P, Throsby M.

Cancer Cell. 2018 May 14;33(5):922-936.e10. doi: 10.1016/j.ccell.2018.04.003.

7.

Taste and smell perception and quality of life during and after systemic therapy for breast cancer.

de Vries YC, Boesveldt S, Kelfkens CS, Posthuma EE, van den Berg MMGA, de Kruif JTCM, Haringhuizen A, Sommeijer DW, Buist N, Grosfeld S, de Graaf C, van Laarhoven HWM, Kampman E, Winkels RM.

Breast Cancer Res Treat. 2018 Jul;170(1):27-34. doi: 10.1007/s10549-018-4720-3. Epub 2018 Feb 23.

8.

A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1.

De Nardis C, Hendriks LJA, Poirier E, Arvinte T, Gros P, Bakker ABH, de Kruif J.

J Biol Chem. 2017 Sep 1;292(35):14706-14717. doi: 10.1074/jbc.M117.793497. Epub 2017 Jun 27.

9.

Weight change during chemotherapy in breast cancer patients: a meta-analysis.

van den Berg MM, Winkels RM, de Kruif JT, van Laarhoven HW, Visser M, de Vries JH, de Vries YC, Kampman E.

BMC Cancer. 2017 Apr 12;17(1):259. doi: 10.1186/s12885-017-3242-4.

10.

Differences in dietary intake during chemotherapy in breast cancer patients compared to women without cancer.

de Vries YC, van den Berg MMGA, de Vries JHM, Boesveldt S, de Kruif JTCM, Buist N, Haringhuizen A, Los M, Sommeijer DW, Timmer-Bonte JHN, van Laarhoven HWM, Visser M, Kampman E, Winkels RM.

Support Care Cancer. 2017 Aug;25(8):2581-2591. doi: 10.1007/s00520-017-3668-x. Epub 2017 Mar 16.

11.

[Thoracic endometriosis with aspecific manifestation].

Hamel CC, de Kruif JH, Jansen JP, Barendregt WB.

Ned Tijdschr Geneeskd. 2016;160:A9883. Dutch.

PMID:
27405565
12.

Complication rate of uterine morcellation in laparoscopic supracervical hysterectomy: a retrospective cohort study.

Smits RM, De Kruif JH, Van Heteren CF.

Eur J Obstet Gynecol Reprod Biol. 2016 Apr;199:179-82. doi: 10.1016/j.ejogrb.2016.02.022. Epub 2016 Feb 21.

PMID:
26943477
13.

On prilled Nanotubes-in-Microgel Oral Systems for protein delivery.

de Kruif JK, Ledergerber G, Garofalo C, Fasler-Kan E, Kuentz M.

Eur J Pharm Biopharm. 2016 Apr;101:90-102. doi: 10.1016/j.ejpb.2016.01.014. Epub 2016 Feb 4.

PMID:
26851504
14.

The Burden of ADHD in Older Adults: A Qualitative Study.

Michielsen M, de Kruif JTCM, Comijs HC, van Mierlo S, Semeijn EJ, Beekman ATF, Deeg DJH, Kooij JJS.

J Atten Disord. 2018 Apr;22(6):591-600. doi: 10.1177/1087054715610001. Epub 2015 Oct 29.

PMID:
26515893
15.

A Systematic Study on Manufacturing of Prilled Microgels into Lipids for Oral Protein Delivery.

De Kruif JK, Varum F, Bravo R, Kuentz M.

J Pharm Sci. 2015 Oct;104(10):3351-65. doi: 10.1002/jps.24526. Epub 2015 Jun 24.

PMID:
26108711
16.

On prilling of hydrophilic microgels in lipid dispersions using mono-N-carboxymethyl chitosan for oral biologicals delivery.

De Kruif JK, Fasler-Kan E, Varum F, Bravo R, Kuentz M.

J Pharm Sci. 2014 Nov;103(11):3675-3687. doi: 10.1002/jps.24172. Epub 2014 Sep 19.

PMID:
25241928
17.
18.
19.

Novel quality by design tools for concentrated drug suspensions: surface energy profiling and the fractal concept of flocculation.

de Kruif JK, Khoo J, Bravo R, Kuentz M.

J Pharm Sci. 2013 Mar;102(3):994-1007. doi: 10.1002/jps.23435. Epub 2012 Dec 29.

PMID:
23280339
20.

Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry.

Rosati S, Thompson NJ, Barendregt A, Hendriks LJ, Bakker AB, de Kruif J, Throsby M, van Duijn E, Heck AJ.

Anal Chem. 2012 Aug 21;84(16):7227-32. doi: 10.1021/ac301611d. Epub 2012 Aug 10.

PMID:
22882109
21.

Metroplasty versus expectant management for women with recurrent miscarriage and a septate uterus.

Kowalik CR, Goddijn M, Emanuel MH, Bongers MY, Spinder T, de Kruif JH, Mol BW, Heineman MJ.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD008576. doi: 10.1002/14651858.CD008576.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Jan 17;1:CD008576.

PMID:
21678380
22.

[Compartment syndrome following laparoscopic procedures in the lithotomy position].

Donckers J, de Kruif JH, van der Stappen WA.

Ned Tijdschr Geneeskd. 2010;154:A1284. Dutch.

PMID:
20619013
23.

Generation of stable cell clones expressing mixtures of human antibodies.

de Kruif J, Kramer A, Nijhuis R, van der Zande V, den Blanken R, Clements C, Visser T, Keehnen R, den Hartog M, Throsby M, Logtenberg T.

Biotechnol Bioeng. 2010 Aug 1;106(5):741-50. doi: 10.1002/bit.22763.

PMID:
20564612
24.

Laparoscopic subtotal hysterectomy versus laparoscopic total hysterectomy: a decade of experience.

van Evert JS, Smeenk JM, Dijkhuizen FP, de Kruif JH, Kluivers KB.

Gynecol Surg. 2010 Feb;7(1):9-12. Epub 2009 Nov 14.

25.

Construction of phage antibody repertoires from the blood of West Nile virus-infected donors.

Throsby M, de Kruif J.

Methods Mol Biol. 2009;562:45-60. doi: 10.1007/978-1-60327-302-2_4.

PMID:
19554286
26.

Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous V(H) genes.

de Kruif J, Kramer A, Visser T, Clements C, Nijhuis R, Cox F, van der Zande V, Smit R, Pinto D, Throsby M, Logtenberg T.

J Mol Biol. 2009 Apr 3;387(3):548-58. doi: 10.1016/j.jmb.2009.02.009. Epub 2009 Feb 11.

PMID:
19361421
27.

Identification of target membrane proteins as detected by phage antibodies.

Geuijen CA, Bakker AQ, de Kruif J.

Methods Mol Biol. 2009;528:141-58. doi: 10.1007/978-1-60327-310-7_11.

PMID:
19153691
28.

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J.

PLoS One. 2008;3(12):e3942. doi: 10.1371/journal.pone.0003942. Epub 2008 Dec 16.

29.

Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.

Throsby M, Ter Meulen J, Geuijen C, Goudsmit J, de Kruif J.

Expert Rev Vaccines. 2007 Apr;6(2):183-91. Review.

PMID:
17408368
30.

A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis.

de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J.

Annu Rev Med. 2007;58:359-68. Review.

PMID:
16886905
31.

Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus.

Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijsters-van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R, Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, ter Meulen J, de Kruif J.

J Virol. 2006 Jul;80(14):6982-92.

32.

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.

ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, Preiser W, Doerr HW, Chow VT, de Kruif J, Peiris JS, Goudsmit J.

PLoS Med. 2006 Jul;3(7):e237.

33.

Case report: retroperitoneoscopic tumor nephrectomy during pregnancy.

van Basten JP, Knipscheer B, de Kruif J.

J Endourol. 2006 Mar;20(3):186-7.

PMID:
16548725
34.

Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.

Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, Hanlon CA, Thijsse S, Backus HH, de Kruif J, Dietzschold B, Rupprecht CE, Goudsmit J.

J Virol. 2005 Jul;79(14):9062-8.

35.

Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery.

Geuijen CA, Clijsters-van der Horst M, Cox F, Rood PM, Throsby M, Jongeneelen MA, Backus HH, van Deventer E, Kruisbeek AM, Goudsmit J, de Kruif J.

J Immunol Methods. 2005 Jul;302(1-2):68-77.

PMID:
15992810
36.

The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries.

Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, Bakker AQ, de Jong M, Jongeneelen M, Thijsse S, Backus HH, Rice AB, Weldon WC, Rupprecht CE, Dietzschold B, Bakker AB, de Kruif J.

Eur J Immunol. 2005 Jul;35(7):2131-45.

37.

Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis.

Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de Kruif J, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB.

J Virol. 2005 Apr;79(8):4672-8.

38.

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.

van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus AD, Preiser W, Doerr HW, de Kruif J, Goudsmit J.

J Virol. 2005 Feb;79(3):1635-44.

39.

A proteomic approach to tumour target identification using phage display, affinity purification and mass spectrometry.

Geuijen CA, Bijl N, Smit RC, Cox F, Throsby M, Visser TJ, Jongeneelen MA, Bakker AB, Kruisbeek AM, Goudsmit J, de Kruif J.

Eur J Cancer. 2005 Jan;41(1):178-87.

PMID:
15618003
40.

C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.

Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, Jongeneelen MA, Visser TJ, Bijl N, Geuijen CA, Marissen WE, Radosevic K, Throsby M, Schuurhuis GJ, Ossenkoppele GJ, de Kruif J, Goudsmit J, Kruisbeek AM.

Cancer Res. 2004 Nov 15;64(22):8443-50.

41.

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.

ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD.

Lancet. 2004 Jun 26;363(9427):2139-41.

PMID:
15220038
42.
44.

A novel helper phage that improves phage display selection efficiency by preventing the amplification of phages without recombinant protein.

Kramer RA, Cox F, van der Horst M, van der Oudenrijn S, Res PC, Bia J, Logtenberg T, de Kruif J.

Nucleic Acids Res. 2003 Jun 1;31(11):e59.

45.

[Foot and mouth disease control].

de Kruif JH.

Tijdschr Diergeneeskd. 2002 Feb 15;127(4):129. Dutch. No abstract available.

PMID:
11885335
46.

Monitoring of neutrophil priming in whole blood by antibodies isolated from a synthetic phage antibody library.

Koenderman L, Kanters D, Maesen B, Raaijmakers J, Lammers JW, de Kruif J, Logtenberg T.

J Leukoc Biol. 2000 Jul;68(1):58-64.

PMID:
10914490
47.

[Fibroids and fertility].

Willemsen WN, de Kruif JH, Velthausz MB, Meelen BT.

Ned Tijdschr Geneeskd. 2000 Apr 22;144(17):789-91. Review. Dutch.

PMID:
10800547
48.

Recombinant lipid-tagged antibody fragments as functional cell-surface receptors.

de Kruif J, Tijmensen M, Goldsein J, Logtenberg T.

Nat Med. 2000 Feb;6(2):223-7. No abstract available.

PMID:
10655115
49.

Limitations of the semisynthetic library approach for obtaining human monoclonal autoantibodies to the thyrotropin receptor of Graves' disease.

Van Der Heijden JH, De Bruin TW, Glaudemans KA, De Kruif J, Banga JP, Logtenberg T.

Clin Exp Immunol. 1999 Nov;118(2):205-12.

50.

A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments.

Huls GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegman L, Boel E, van der Vuurst de Vries AR, Loyson SA, Helfrich W, van Berge Henegouwen GP, van Meijer M, de Kruif J, Logtenberg T.

Nat Biotechnol. 1999 Mar;17(3):276-81.

PMID:
10096296

Supplemental Content

Loading ...
Support Center